IR@PKUHSC  > 北京大学第二临床医学院
学科主题临床医学
Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B
Hou, Jin-Lin1; Xu, Daozheng2; Shi, Guangfeng3; Wan, Mobin4; Goodman, Zachary5; Tan, Deming6; Xie, Qing7; Chen, Chengwei8; Wei, Lai9; Niu, Junqi10; Wang, Qinhuan11; Ren, Hong12; Wang, Yuming13; Jia, Jidong14; Bao, Weibin15; Dong, Yuhong16; Trylesinski, Aldo16; Naoumov, Nikolai V.16
关键词Chronic hepatitis B Ishak fibrosis score Knodell necroinflammatory score Liver biopsy Telbivudine
刊名ADVANCES IN THERAPY
2015-08-01
DOI10.1007/s12325-015-0232-2
32期:8页:727-741
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, Research & Experimental ; Pharmacology & Pharmacy
资助者Novartis ; National Science and Technology Major Project ; Novartis Pharma AG ; Novartis ; National Science and Technology Major Project ; Novartis Pharma AG
研究领域[WOS]Research & Experimental Medicine ; Pharmacology & Pharmacy
关键词[WOS]SUSTAINED VIROLOGICAL RESPONSE ; TENOFOVIR DISOPROXIL FUMARATE ; HEPATOCELLULAR-CARCINOMA ; VIRAL LOAD ; TRANSIENT ELASTOGRAPHY ; LAMIVUDINE THERAPY ; ADEFOVIR DIPIVOXIL ; POSITIVE PATIENTS ; DNA LEVEL ; CIRRHOSIS
英文摘要

The long-term goal of chronic hepatitis B (CHB) treatment is improvement of liver disease and prevention of cirrhosis. The aim of this study was to assess whether prolonged telbivudine treatment improves liver inflammation and fibrosis. The primary objective was to evaluate the proportion of patients with absence/minimal inflammation (Knodell necroinflammatory score a parts per thousand currency sign3) on liver biopsy at Year 5.

Fifty-seven patients aged 16-70 years with a clinical history of CHB and active viral replication (38 hepatitis B e antigen [HBeAg] positive and 19 HBeAg negative) were followed for 6 years: 33 received telbivudine 600 mg/day continuously for 5 years; 24 received lamivudine 100 mg/day for 2 years and then telbivudine for 3 years. Liver biopsies were taken pre-treatment and after 5 years of treatment.

At baseline, mean (standard deviation) serum hepatitis B virus (HBV) DNA load was 8.5 (1.7) log(10) copies/mL, Knodell necroinflammatory score was 7.6 (2.9), and Ishak fibrosis score was 2.2 (1.1). After antiviral treatment (median duration: 261 weeks), liver histology improved with increased proportions of patients with absence/minimal liver inflammation (Knodell necroinflammatory score a parts per thousand currency sign3), from 16% (9/57) at baseline to 98% (56/57), and absence/minimal fibrosis (Ishak score a parts per thousand currency sign1), from 25% (14/57) at baseline to 84% (48/57). At Year 5, HBV DNA load was < 300 copies/mL for all patients; cumulative HBeAg loss and seroconversion rates were 88% and 77%, respectively. At Year 6, 95% of patients with abnormal baseline glomerular filtration rate (60-90 mL/min/1.73 m(2)) improved to normal GFR (> 90 mL/min/1.73 m(2)).

Long-term telbivudine treatment with profound and durable viral suppression significantly improved liver histology, thus achieving the long-term goals of CHB treatment. FibroScan(A (R)) results after 5 and 6 years of treatment (in almost 20% of patients) were consistent with this information.

Novartis and National Science and Technology Major Project (2012ZX10002003).

ClinicalTrials.gov # NCT00877149.

语种英语
所属项目编号2012ZX10002003
资助者Novartis ; National Science and Technology Major Project ; Novartis Pharma AG ; Novartis ; National Science and Technology Major Project ; Novartis Pharma AG
WOS记录号WOS:000361437000002
引用统计
被引频次:4[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/67448
专题北京大学第二临床医学院
作者单位1.Nanjing Mil Area, Shanghai Liver Dis Res Ctr, Shanghai, Peoples R China
2.Peking Univ, Peoples Hosp, Beijing 100871, Peoples R China
3.1 Hosp, Changchun, Peoples R China
4.First Hosp Peking, Beijing, Peoples R China
5.Xi Nan Hosp, Chongqing, Peoples R China
6.Beijing Friendship Hosp, Beijing, Peoples R China
7.Novartis Pharma Corp, E Hanover, NJ USA
8.Xiangya Hosp, Changsha, Hunan, Peoples R China
9.Novartis Pharma AG, Basel, Switzerland
10.Beijing Ditan Hosp, Beijing, Peoples R China
11.Shanghai Changhai Hosp, Shanghai, Peoples R China
12.Inova Fairfax Hosp, Ctr Liver Dis, Falls Church, VA USA
13.Southern Med Univ, Nanfang Hosp, Hepatol Unit, Dept Infect Dis, Guangzhou 510515, Guangdong, Peoples R China
14.Fu Dan Univ, Huashan Hosp, Dept Infect Dis, Shanghai, Peoples R China
15.Shanghai Jiao Tong Univ, Ruijin Hosp, Sch Med, Shanghai 200030, Peoples R China
16.Chongqing Med Univ, Affiliated Hosp 2, Chongqing, Peoples R China
推荐引用方式
GB/T 7714
Hou, Jin-Lin,Xu, Daozheng,Shi, Guangfeng,et al. Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B[J]. ADVANCES IN THERAPY,2015,32(8):727-741.
APA Hou, Jin-Lin.,Xu, Daozheng.,Shi, Guangfeng.,Wan, Mobin.,Goodman, Zachary.,...&Naoumov, Nikolai V..(2015).Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B.ADVANCES IN THERAPY,32(8),727-741.
MLA Hou, Jin-Lin,et al."Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B".ADVANCES IN THERAPY 32.8(2015):727-741.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Hou, Jin-Lin]的文章
[Xu, Daozheng]的文章
[Shi, Guangfeng]的文章
百度学术
百度学术中相似的文章
[Hou, Jin-Lin]的文章
[Xu, Daozheng]的文章
[Shi, Guangfeng]的文章
必应学术
必应学术中相似的文章
[Hou, Jin-Lin]的文章
[Xu, Daozheng]的文章
[Shi, Guangfeng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。